Now signed, the EU–UK Trade Deal is an agreement applied provisionally since 1 January 2021, when the Brexit transition period ended. It requires Healthcare and Life Science companies and their commercial partners to make major changes to the ways that they conduct R&D, Manufacturing, Clinical Development, supply chain logistics, procurement, product distribution and warehousing. There are legal and regulatory changes peculiar to England & Wales and Scotland; Northern Ireland and the Republic of Ireland. Arthur Cox (legal) then PharmaLex (Regulatory) experts will provide respective updates for UK, EU and international webinar delegates. There will be the chance for Q&A on the most recent updates and ongoing preparations for future post-Brexit developments. There is published guidance from law makers and regulators, setting out their positions and rules. However, there are also gaps where expert interpretation is best taken, not only for long-term compliance but to also get ahead.
Senior Consultant & Director, PharmaLex
Graham is a Director, Regulatory Affairs at PharmaLex UK. Graham has over 15 years experience in pharmaceutical regulatory consultancy. Graham leads PharmaLex’s UK and Ireland Regulatory Centre of Excellence service delivery area. He advises a wide range of companies about their regulatory activities in the UK and Ireland.
Corporate, Commercial and Regulatory Lawyer focusing on the life sciences and communications industries, Arthur Cox
Colin is a partner in the Corporate and M&A Group at Arthur Cox Solicitors in Dublin. Colin is head of the firm’s Life Sciences group and provides corporate, commercial and regulatory advice to international and Irish life sciences companies doing business in Ireland.